Atavistik Bio and Pfizer collaborate to develop new precision cancer treatments.

Atavistik Bio, a biotech firm specializing in precision allosteric therapeutics, has teamed up with Pfizer to accelerate the discovery of new treatments for unmet medical needs. Using Atavistik Bio's AMPS™ platform, the companies will identify novel allosteric binders for two undisclosed targets, aiming to expand the potential of precision oncology therapies. Pfizer has the option to license the resulting programs post-research.

3 months ago
5 Articles

Further Reading